Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.
Also called NCT01338870
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 301 participants
- Sponsor
- Registry
-
NCT01338870
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Hungary, Mexico, Slovakia, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01338870. Randomized; double masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-04-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- 25 mg PF-04991532
- Intervention (Drug)
- 75 mg PF-04991532
- Intervention (Drug)
- 150 mg PF-04991532
- Intervention (Drug)
- 300 mg PF-04991532
- Intervention (Drug)
- Sitagliptin 100 mg
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01338870- Content hash
b0c2c5963d8f8f6b44dedcd75f003565d313a47ea0d715143d5c84c3b510d610